QIAGEN NV Form 6-K November 14, 2011 **Table of Contents**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2011
Commission File Number 0-28564
QIAGEN N.V.
Spoorstraat 50
5911 KJ Venlo
The Netherlands
Indicate by check mark whether the registrant files or will file annual n
Form 20-F x Form 40-F "
Indicate by check mark whether the registrant is submitting the Form 6

eports under cover of Form 20-F or Form 40-F:

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): "

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): "

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes " No x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Table of Contents

QIAGEN N.V. Form 6-K

TABLE OF CONTENTS

ItemPageOther Information3Signatures4Exhibit Index5

Table of Contents

OTHER INFORMATION

For the three- and nine-month periods ended September 30, 2011, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

BY: /S/ ROLAND SACKERS

Roland Sackers

Chief Financial Officer

Date: November 14, 2011

EXHIBIT INDEX

Exhibit Exhibit

No.

99.1 U.S. GAAP Quarterly Report for the Period Ended September 30, 2011

Table of Contents

Exhibit 99.1

QIAGEN N.V. AND SUBSIDIARIES

U.S. GAAP QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2011

TABLE OF CONTENTS

Financial Information

Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010	<u>2</u>
Condensed Consolidated Statements of Income (unaudited) for the three months ended September 30, 2011 and 2010	<u>4</u>
Condensed Consolidated Statements of Income (unaudited) for the nine months ended September 30, 2011 and 2010	<u>5</u>
Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2011 and 2010	<u>6</u>
Condensed Consolidated Statements of Changes in Equity (unaudited) for the nine months ended September 30, 2011 and 2010	7
Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2011 and 2010	<u>8</u>
Notes to Condensed Consolidated Financial Statements (unaudited)	9
Operating and Financial Review and Prospects	<u>22</u>
Quantitative and Qualitative Disclosures About Market Risk	<u>28</u>
Recent Authoritative Pronouncements	<u>29</u>
Application of Critical Accounting Policies, Judgments and Estimates	<u>29</u>
Off-Balance Sheet Arrangements	<u>29</u>
Contractual Obligations	<u>29</u>
<u>Legal Proceedings</u>	<u>29</u>
Risk Factors	<u>30</u>
1	

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in \$ thousands)

	Note	September 30, 2011 (unaudited)	December 31, 2010
Assets			
Current assets:			
Cash and cash equivalents		\$ 393,850	\$ 828,407
Short-term investments		92,497	106,077
Accounts receivable, net of allowance for doubtful accounts of \$4,319 and \$3,227 in 2011 and 2010, respectively		211,088	197,418
Income taxes receivable		14,011	10,920
Inventories, net	(10)	145,531	126,633
Prepaid expenses and other current assets		90,014	64,402
Deferred income taxes		26,717	30,731
Total current assets		973,708	1,364,588
Long-term assets:			
Property, plant and equipment, net		373,620	345,664
Goodwill	(11)	1,658,598	1,352,281
Intangible assets, net of accumulated amortization of \$392,446 and \$312,326 in	(11)	854,199	752 227
2011 and 2010, respectively	(11)	034,199	753,327
Deferred income taxes		20,910	37,182
Other assets		67,407	60,953
Total long-term assets		2,974,734	2,549,407
Total assets		\$ 3,948,442	\$ 3,913,995

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(in \$ thousands, except par value)

	Note	September 30, 2011 (unaudited)	December 31, 2010
Liabilities and equity			
Current liabilities:			
Accounts payable		\$ 44,900	\$ 47,803
Accrued and other liabilities (of which \$10,329 and \$6,296 due to related	(15)	194,599	209,054
parties in 2011 and 2010, respectively)	(13)	174,377	207,034
Income taxes payable		21,179	25,211
Current portion of long-term debt	(9)	351,661	75,835
Deferred income taxes		35,841	30,504
Total current liabilities		648,180	388,407
Long-term Liabilities:			
Long-term debt, net of current portion (of which \$445,000 in 2011 and 2010	(0) (15)	446,505	797,171
due to related parties)	()) (13)	440,505	777,171
Deferred income taxes		218,521	200,667
Other liabilities		50,713	51,397
Total long-term liabilities		715,739	1,049,235
Commitments and contingencies	(14)		
Equity:			
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no sha	res		
issued and outstanding			
Financing preference shares, 0.01 EUR par value, authorized—40,000 share	es,		
no shares issued and outstanding		<u> </u>	_
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued a	ınd	2,738	2,724
outstanding—234,118 and 233,115 shares in 2011 and 2010, respectively		2,736	2,724
Additional paid-in capital		1,674,558	1,648,985
Retained earnings		856,304	759,890
Accumulated other comprehensive income	(13)	9,155	64,754
Equity attributable to the owners of QIAGEN N.V.		2,542,755	2,476,353
Noncontrolling interest		41,768	_
Total equity		2,584,523	2,476,353
Total liabilities and equity		\$ 3,948,442	\$ 3,913,995

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in \$ thousands, except per share data)

	Three Mont	ths Ended	
	September 3	30,	
	2011	2010	
	(unaudited)		
Net sales	\$288,885	\$274,317	
Cost of sales	101,353	93,797	
Gross profit	187,532	180,520	
Operating expenses:			
Research and development	32,646	30,980	
Sales and marketing	80,143	66,941	
General and administrative, integration and other	33,705	26,484	
Acquisition-related intangible amortization	6,741	5,880	
Total operating expenses	153,235	130,285	
Income from operations	34,297	50,235	
Other income (expense):			
Interest income	2,335	1,227	
Interest expense	(6,537)	(6,980)
Other income, net	12,910	2,374	
Total other income (expense)	8,708	(3,379)
Income before provision for income taxes	43,005	46,856	
Provision for income taxes	8,538	10,368	
Net income	34,467	36,488	
Net (loss) attributable to noncontrolling interest	(678)		
Net income attributable to the owners of QIAGEN N.V.	\$35,145	\$36,488	
Basic net income per common share attributable to the owners of QIAGEN N.V.	\$0.15	\$0.16	
Diluted net income per common share attributable to the owners of QIAGEN N.V.	\$0.15	\$0.15	
Weighted-average shares outstanding (in thousands)			
Basic	234,042	232,769	
Diluted	238,227	238,977	

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in \$ thousands, except per share data)

	Nine Mont			
	September			
	2011		2010	
Net sales	(unaudited)		¢001 200	
Net sales	\$835,327		\$801,399	
Cost of sales	287,237		274,861	
Gross profit	548,090		526,538	
Operating expenses:				
Research and development	97,822		92,001	
Sales and marketing	225,013		197,632	
General and administrative, integration and other	86,916		81,262	
Acquisition-related intangible amortization	19,141		17,878	
Total operating expenses	428,892		388,773	
Income from operations	119,198		137,765	
Other income (expense):				
Interest income	4,939		3,416	
Interest expense	(19,481)	(20,903)
Other income, net	13,607		7,469	
Total other expense	(935)	(10,018)
Income before provision for income taxes	118,263		127,747	
Provision for income taxes	22,527		19,725	
Net income	95,736		108,022	
Net (loss) attributable to noncontrolling interest	(678)		
Net income attributable to the owners of QIAGEN N.V.	\$96,414		\$108,022	
Basic net income per common share attributable to the owners of QIAGEN N.V.	\$0.41		\$0.46	
Diluted net income per common share attributable to the owners of QIAGEN N.V.	\$0.40		\$0.45	
			,	
Weighted-average shares outstanding (in thousands)				
Basic	233,748		232,519	
Diluted	239,864		240,846	
The accompanying notes are an integral part of these condensed consolidated financial st	atements.			

Table of Contents

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (in \$ thousands)

		Three Mor September			
No	ote	2011	30	, 2010	
		(unaudited)	2010	
Net income		\$34,467		\$36,488	
Gains (losses) on cash flow hedges, before tax (7))	11,456		(17,146)
Reclassification adjustments on cash flow hedges, before tax (7))	(12,649)	19,344	
Cash flow hedges, before tax		(1,193)	2,198	
Foreign currency translation adjustments, before tax		(91,614)	54,878	
Other comprehensive (loss) income, before tax		(92,807)	57,076	
Income tax relating to components of other comprehensive (loss) income		(1,435)	(2,455)
Total other comprehensive (loss) income, after tax		(94,242)	54,621	
Comprehensive (loss) income		(59,775)	91,109	
Comprehensive (loss) attributable to the noncontrolling interest		(670)		
Comprehensive (loss) income attributable to the owners of QIAGEN N.V.		\$(59,105)	\$91,109	
		Nine Mont	hs	Ended	
		September	30),	
No	ote	2011		2010	
		(unaudited)		
Net income		\$95,736		\$108,022	
Gains on cash flow hedges, before tax (7))	532		10,889	
Reclassification adjustments on cash flow hedges, before tax (7))	894		(5,426)
Cash flow hedges, before tax		1,426		5,463	
Foreign currency translation adjustments, before tax		(55,398)	7,308	
Other comprehensive (loss) income, before tax		(53,972	-	12,771	
Income tax relating to components of other comprehensive (loss) income		(1,619)	(1,241)
Total other comprehensive (loss) income, after tax		(55,591)	11,530	
Comprehensive income		40,145		119,552	
Comprehensive (loss) attributable to the noncontrolling interest Comprehensive income attributable to the owners of QIAGEN N.V.		(670 \$40,815)	 \$119,552	

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (in \$ thousands, except share amounts)

Equity attributable	to the owners	of QIAGEN N.V.
---------------------	---------------	----------------

(unaudited) Note Common Shares								
		Shares	Amount	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensiv Income	Non-controlli eInterest	ngotal Equity
BALANCE AT DECEMBER 31, 2010		233,115	\$2,724	\$1,648,985	\$759,890	\$ 64,754	\$ —	\$2,476,353
Acquisition of Ipsogen S.A.	(5)		_	_	_	_	42,438	42,438
Net income		_	_	_	96,414	_	(678)	95,736
Proceeds from subscription receivables		_	_	621	_	_	_	621
Unrealized gain, net on hedging contracts	.	_	_	_	_	347	_	347
Realized loss, net on hedging contracts		_	_	_	_	514		514
Translation adjustment, net	(13)	_		_	_	(56,460)	8	(56,452)
Issuance of common shares in connection with stock plan		1,003	14	8,416	_	_	_	8,430
Share-based compensation	(3)	_	_	14,321	_	_	_	14,321
Excess tax benefit of employee stock plans		_		2,215	_	_	_	2,215
BALANCE AT SEPTEMBER 30, 2011		234,118	\$2,738	\$1,674,558	\$856,304	\$ 9,155	\$ 41,768	\$2,584,523
BALANCE AT DECEMBER 31, 2009		232,074	\$2,711	\$1,622,733	\$615,579	\$ 50,146	\$ —	\$2,291,169
Net income		_	_	_	108,022	_		108,022
Proceeds from subscription receivables		_		606	_	_	_	606
Unrealized gain, net on hedging contracts		_	_	_	_	7,313	_	7,313
Realized gain, net on hedging contracts	1	_		_	_	(3,668)		(3,668)
Translation adjustment, net		_		_	_	7,883	_	7,883

Issuance of common shares in connection with stock plan		758	10	7,542	_	_	_	7,552
Share-based compensation	(3)		_	9,958	_		_	